FluoGuide A/S
SSTO:FLUO30.90
SEK
-0.70
(-2.22%)
FluoGuide A/S
STO:FLUO
(Nasdaq Stockholm)
Recent
price
30.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
DKK
•
in mil. unless spec.Working Capital
DKK
•
in mil. unless spec.Growth Rates
DKK
•
in mil. unless spec.Quarterly Revenue
DKK
•
in mil. unless spec.Quarterly Earnings Per Share
DKK
•
in mil. unless spec.Quarterly Dividends Per Share
DKK
•
in mil. unless spec.- Similar Companies
- Business
- FluoGuide A/S is a Denmark-based biotechnology company specializing in precision cancer surgery solutions aimed at improving surgical outcomes for cancer patients. The company’s primary product, FG001, is a fluorescent agent designed to enhance surgical accuracy by illuminating cancerous tissue intraoperatively, thereby enabling more precise tumor removal. FG001 is clinically proven to guide surgeons in removing additional cancer tissue in brain cancers such as high-grade glioma as well as lung and head and neck cancers. In addition to its surgical guidance capabilities, FG001 also holds potential therapeutic applications as a photosensitizer for photothermal and photodynamic therapies. FluoGuide operates primarily in the medical technology and biotech sectors, targeting healthcare providers involved in oncology surgery worldwide. The company was founded in 2018 and is headquartered in Copenhagen, Denmark. Recent major developments at FluoGuide include strategic collaborations established in 2024 and 2025 with leading global MedTech companies to advance FG001’s clinical applications and commercialization efforts. In March 2024, FluoGuide entered a collaboration with Intuitive Surgical to develop FG001 for robotic-assisted surgeries in head and neck cancer treatment. In July 2025, FluoGuide announced a partnership with Olympus to jointly develop FG001 for tumor imaging and surgical margin assessment in head and neck cancer, leveraging Olympus’s endoscopic imaging platforms. Additionally, in late 2025, FluoGuide signed a collaboration agreement with ZEISS, a company renowned for surgical microscopy, to further enhance the clinical use of FG001. The company also received positive interim clinical results in 2025 for FG001 in brain tumors, including meningioma and low-grade glioma, which supports its development pipeline. FluoGuide completed a directed share issue raising SEK 104 million in 2025 to strengthen its funding base and clinical program advancement. Collectively, FluoGuide’s product portfolio and strategic partnerships place it at the forefront of molecular imaging and precision surgical solutions designed to reduce cancer recurrence, minimize surgical complications, and lower healthcare costs through better cancer surgery outcomes. This profile reflects information current as of late 2025.